AVE Share Price Performance
AU$0.0045
0.00 (50.00%)
Price AU$0.0045
Share PriceAU$0.0045
AVE Community Narratives
There are no narratives available yet.
Recent AVE News & Updates
No updates
Avecho Biotechnology Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.00098
- Gross Margin
- 59.32%
- Net Profit Margin
- -275.64%
- Debt/Equity Ratio
- 29.9%
Avecho Biotechnology Limited Competitors
About AVE
- Founded
- 1992
- Employees
- n/a
- CEO
- WebsiteView website
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery. Its human health portfolio covers delivery of pharmaceutical products for pain and dermatology applications through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Australian Market Performance
- 7 Days: 0.7%
- 3 Months: 7.6%
- 1 Year: 14.0%
- Year to Date: 6.4%
The Consumer Discretionary sector gained 3.1% while the market remained flat over the last week. More promisingly, the market is up 14% over the past year. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading